Abstract
Although there is strong evidence that ligand activation of peroxisome proliferator-activated receptor (PPAR)-β/δ induces terminal differentiation and attenuates cell growth, some studies suggest that PPARβ/δ actually enhances cell proliferation. For example, it was suggested recently that retinoic acid (RA) is a ligand for PPARβ/δ and potentiates cell proliferation by activating PPARβ/δ. The present study examined the effect of ligand activation of PPARβ/δ on cell proliferation, cell cycle kinetics, and target gene expression in human HaCaT keratinocytes using two highly specific PPARβ/δ ligands [4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy acetic acid (GW0742) and 2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)-methylsulfanyl)phenoxy-acetic acid (GW501516)] and RA. Both PPARβ/δ ligands and RA inhibited cell proliferation of HaCaT keratinocytes. GW0742 and GW501516 increased expression of known PPARβ/δ target genes, whereas RA did not; RA increased the expression of known retinoic acid receptor/retinoid X receptor target genes, whereas GW0742 did not affect these genes. GW0742, GW501516, and RA did not modulate the expression of 3-phosphoinositide-dependent protein kinase or alter protein kinase B phosphorylation. GW0742 and RA increased annexin V staining as quantitatively determined by flow cytometry. The effects of GW0742 and RA were also examined in wild-type and PPARβ/δ-null primary mouse keratinocytes to determine the specific role of PPARβ/δ in modulating cell growth. Although inhibition of keratinocyte proliferation by GW0742 was PPARβ/δ-dependent, inhibition of cell proliferation by RA occurred in both genotypes. Results from these studies demonstrate that ligand activation of PPARβ/δ inhibits keratinocyte proliferation through PPARβ/δ-dependent mechanisms. In contrast, the observed inhibition of cell proliferation in mouse and human keratinocytes by RA is mediated by PPARβ/δ-independent mechanisms and is inconsistent with the notion that RA potentiates cell proliferation by activating PPARβ/δ.
Footnotes
-
This work was supported by a National Science Foundation Graduate Research Fellowship and by National Institutes of Health grants CA124533 (to J.M.P.) and CA90214 (to A.C.R.).
-
ABBREVIATIONS: PPAR, peroxisome proliferator-activated receptor; 9-cis RA, 9-cis retinoic acid; ADRP, adipocyte differentiation-related protein; ANOVA, analysis of variance; Angptl4, angiopoietin-like protein 4; Akt, protein kinase B; atRA, all-trans retinoic acid; DMSO, dimethyl sulfoxide; DMEM, Dulbecco's minimal essential medium; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ILK, integrin-linked kinase; PDPK1, 3-phosphoinositide-dependent protein kinase 1; PCR, polymerase chain reaction; PTEN, phosphatase and tensin homolog deleted on chromosome ten; MOPS, 3-(N-morpholino)propanesulfonic acid; PARP, poly(ADP-ribose) polymerase; PI, propidium iodine; RA, retinoic acid; RAR, retinoic acid receptor; RXR, retinoid X receptor; GW0742, 4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2-methylphenoxy acetic acid; GW501516, 2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)-methylsulfanyl)phenoxy-acetic acid; FITC, fluorescein isothiocyanate; SPR1A, small proline-rich protein 1A.
-
↵ The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received July 16, 2008.
- Accepted August 6, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|